Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study

Table 1 Baseline characteristics of all patients and patients with/ without an increase in LDL-C after pemafibrate

Characteristic	Total	Increased LDL-C group (group I)^a	No LDL-C increase group (group NI)^b	P*
Cases no. (%)	51(100)	25 (49)	26 (51)
Cases of LDL-C increase, no. (%)	35 (69)	25 (100)	10 (38)
% increase in LDL-C, median (IQR)	5.3 (−3.8–19.1)	19.1 (13.3–56.3)	− 3.7 (−13.0–1.2)
Males, no. (%)	28 (55)	17 (68)	11 (42)	0.0653
Age, mean (SD), years	62.2 (12.9)	60.7 (13.2)	63.7 (12.7)	0.4168
BMI, mean (SD), kg/m²	26.6 (3.7)	27.1 (4.0)	26.1 (3.4)	0.3496
HbA1c, mean (SD), %	7.4 (1.4)	7.2 (1.3)	7.5 (1.5)	0.5568
eGFR, mean (SD), mL /min/1.73 m²	71.9 (22.3)	74.8 (23.4)	69.2 (21.3)	0.3732
Complications
Hypertension, no. (%)	30 (59)	14 (56)	16 (62)	0.6879
CVD/stroke, no. (%)	9 (18)	6 (24)	3 (12)	0.2432
Treatment for diabetes
OHA, no. (%)	36 (71)	16 (64)	20 (77)	0.4685
Insulin + OHA, no. (%)	4 (8)	3 (12)	1 (4)	0.4685

^a% increase in LDL-C > 5.3%; ^b% increase in LDL-C < 5.3%. P < 0.05 was considered statistically significant (χ² test or t-test). *Statistical analysis between increased LDL-C and no LDL-C increase groups using the χ² test or the t-test. BMI Body mass index, HbA1c Glycated hemoglobin, eGFR Estimated glomerular filtration rate, LDL-C Low density lipoprotein cholesterol, IQR Inter-quartile range, OHA ORAL hypoglycemic agents.

ISSN: 1476-511X